Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol
Source: Human Reproduction, Volume 14, Number 2, February 1999 , pp. 485-488(4)
Publisher: Oxford University Press
Abstract:In this two centre study, the efficacy of 200 mg mifepristone orally followed 48 h later by 0.4 mg misoprostol orally for menstrual regulation was investigated. The dose of mifepristone was taken the day before the expected day of menstruation. Each volunteer was planned to participate for up to 6 months. A plasma β human chorionic gonadotrophin (HCG) was measured on the day of mifepristone intake. The study was disrupted prematurely due to low efficacy. In 125 treatment cycles the overall pregnancy rate was 17.6% (22 pregnancies) and the rate of continuing pregnancies (failure) was 4.0%. Eight women discontinued the study due to bleeding irregularities which were seen in 15 cycles (12%). These effects on bleeding pattern made the timing of treatment day difficult. Late luteal phase treatment with a combination of mifepristone and misoprostol is not adequately effective for menstrual regulation.
Keywords: luteal phase treatment/menstrual regulation/mifepristone/misoprostol
Document Type: Research Article
Affiliations: 1: Department of Obstetrics and Gynecology, Huddinge University Hospital, S-141 86 Huddinge, Sweden 2: Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden 3: Shanghai Institute of Planned Parenthood Research, Shanghai, China 4: Shanghai Lu Wan District MCH Hospital and 5: Shanghai No. 2 Textile Hospital, China
Publication date: February 1999
- Human Reproduction features full-length, peer-reviewed papers reporting original research, clinical case histories, as well as opinions and debates on topical issues. Papers published cover the scientific and medical aspects of reproductive physiology and pathology, endocrinology, andrology, gonad function, gametogenesis, fertilization, embryo development, implantation, pregnancy, genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception, infertility treatment, psychology, ethics and social issues. The highest scientific and editorial standard is maintained throughout the journal along with a rapid rate of publication.